Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Using machine learning to predict the outcomes of patients with NDMM being treated with VRd

Jamin Koo, PhD, Stanford University, Stanford, CA, shares some insights into a study which uses machine learning-assisted risk stratification to predict the outcomes of patients with newly diagnosed multiple myeloma (NDMM) being treated with bortezomib, lenalidomide and dexamethasone (VRd). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Cofounder of ImpriMed